RNAC Stock Summary and Trading Ideas (Cartesian Therapeutics | NASDAQ:RNAC)

Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering cell therapy for the treatment of autoimmune diseases. The company uses technology and a manufacturing platform to introduce mRNA into cells to provide a therapeutic effect to patients suffering from a variety of autoimmune conditions. Unlike DNA, mRNA degrades naturally over time without integrating into the cell's genetic material.

Cartesian Therapeutics trades on the NASDAQ stock market under the symbol RNAC.

As of June 12, 2026, RNAC stock price climbed to $9.51 with 861,178 million shares trading.

RNAC has a beta of 2.62, meaning it tends to be more sensitive to market movements. RNAC has a correlation of 0.11 to the broad based SPY ETF.

RNAC has a market cap of $278.67 million. This is considered a Small Cap stock.

Last quarter Cartesian Therapeutics reported $78,000 in Revenue and -$1.46 earnings per share. This fell short of revenue expectation by $-127,912 and missed earnings estimates by -$.73.

The top ETF exchange traded funds that RNAC belongs to (by Net Assets): VTI, IWM, VXF, IWN, VTWO.

RNAC has underperformed the market in the last year with a return of -7.1%, while SPY returned +24.1%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in RNAC shares. However, RNAC has outperformed the market in the last 3 month and 2 week periods, returning +17.1% and +26.1%, while SPY returned +11.6% and -1.9%, respectively. This indicates RNAC has been having a stronger performance recently.

RNAC support price is $7.43 and resistance is $8.69 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RNAC shares will trade within this expected range on the day.